Efficacy and Safety of Temozolomide Combined with Radiotherapy in the Treatment of Malignant Glioma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Healthcare Engineering"
DOI: 10.1155/2022/3477918
Abstract: MG is a clinical common intracranial tumor, with the characteristics of strong invasion. In our study, we aim to explore the efficacy and safety of temozolomide combined with radiotherapy in the treatment of malignant glioma… read more here.
Keywords: combined radiotherapy; efficacy; group; temozolomide combined ... See more keywords
A Retrospective Trail Investigating Temozolomide Neoadjuvant Chemotherapy Combined with Radiotherapy in Low-Grade Pituitary Tumors
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology"
DOI: 10.1155/2022/4618664
Abstract: Objective To study and analyze the clinical application of temozolomide (TMZ) combined with radiotherapy in the treatment of low-grade pituitary tumors. Methods A retrospective trail was conducted among 67 patients with low-grade pituitary tumors who… read more here.
Keywords: pituitary tumors; combined radiotherapy; group; grade pituitary ... See more keywords
PD-1 inhibitor combined with radiotherapy and GM-CSF as salvage therapy in patients with chemotherapy-refractory metastatic solid tumors.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e15173
Abstract: e15173Background: Patients with refractory metastatic solid tumors have poor prognoses and few therapeutic options. The application of PD-1 inhibitor has led to a paradigm shift in the treatment of... read more here.
Keywords: inhibitor combined; solid tumors; radiotherapy csf; refractory metastatic ... See more keywords
Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and antiangiogenic drugs for hepatocellular carcinoma: a systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2023 at "European review for medical and pharmacological sciences"
DOI: 10.26355/eurrev_202302_31390
Abstract: OBJECTIVE The triplet regimen based on the programmed cell death 1 (PD1)/ programmed cell death ligand 1 (PDL1) inhibitors combined radiotherapy and antiangiogenic drugs is a novel therapeutic strategy for hepatocellular carcinoma. We conducted a… read more here.
Keywords: hepatocellular carcinoma; inhibitors combined; pdl1 inhibitors; combined radiotherapy ... See more keywords